The CART-BCMA/CS1 bispecific CAR-T cell therapy is positioned to address a significant unmet need in the treatment of relapsed/refractory multiple myeloma (MM), particularly for patients who have undergone multiple lines of prior therapy. The market for MM therapies is expanding, with increasing demand for innovative treatments that improve patient outcomes. Given the competitive landscape, which includes established therapies and emerging CAR-T products, successful demonstration of safety and efficacy in this trial could enhance market positioning and attract partnerships or acquisition interest. However, the trial's withdrawal before opening raises concerns regarding feasibility and resource allocation, necessitating further diligence on the sponsor's capabilities and strategic direction.